Pain Workshop  |  Biotechnology Workshop  |  Day 1 Companies  |  Day 2 Companies

Tuesday, March 4, 2008
Pain Workshop
Keynote Address	Why Does Pain Matter? Nathaniel Katz, MD, MS, Analgesic Research and Angela Larson, Susquehanna Financial Group
Panel I	Drug Development/Market Status Russell K. Portenoy, MD, Chairman, Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, and Professor of Neurology and Anesthesiology, Albert Einstein College of Medicine
	The Current Status of Development Efforts William (Bill) Schmidt, PhD, NorthStar Consulting, LLC, previously VP, Clinical Research, Renovis Inc.; VP, Scientific Affairs, Adolor Corporation; Immediate Past President of the Eastern Pain Association, DuPont Pharmaceuticals
Panel II	The Investor Challenge Angela Larson, SFG, Research Analyst
	Regulatory Reality Cynthia McCormick, MD, President, McCormick Consultation LLC; former Director of the FDA’s Division of Anesthetic, Critical Care and Addiction Drug Products
Panel III	Patents and Innovation Robert J. Paradiso, Esq., Lowenstein Sandler, PC, Head of Life Sciences Patent Practice
	CEO/Industry Reality Perspective Joseph Stauffer, DO, Chief Medical Officer, SVP, Clinical Research & Medical Affairs, Alpharma, Inc. (ALO), Adjunct Assistant Professor, Johns Hopkins University Hospital Department of Anesthesiology, Division of Pain Medicine, Former FDA Medical Review Officer, Analgesic Drugs; Jennifer Good, President and Chief Executive Officer, Penwest Pharmaceuticals Co.
Company Presentations
2:45 p.m.	DURECT Corporation (DRRX)
3:00 p.m.	Alpharma, Inc. (ALO)
3:15 p.m.	King Pharmaceuticals, Inc. (KG)
3:30 p.m.	Depomed, Inc. (DEPO)
3:45 p.m.	Q&A round table
4:00 p.m.	NeurogesX, Inc. (NGSX)
4:15 p.m.	Penwest Pharmaceuticals Co. (PPCO)
4:30 p.m.	Cadence Pharmaceuticals, Inc. (CADX)
4:45 p.m.	Array BioPharma Inc. (ARRY)
5:00 p.m.	Q&A round table

Tuesday, March 4, 2008
Time (ET)	Sea/Ocean Room	Arbor Boardroom
8:00 a.m.	GlobeImmune (private)	Ivivi Technologies Inc. (IVVI)
8:30 a.m.	Genelabs Technologies Inc. (GNLB)	Transcept Pharmaceuticals (private)
9:00 a.m.	La Jolla Pharmaceutical Co. (LJPC)	SIGA Technologies Inc. (SIGA)
9:30 a.m.	Synta Pharmaceuticals Corp. (SNTA)	QuatRx Pharmaceuticals (private)
10:00 a.m.	Exelixis Inc. (EXEL)	Micromet, Inc. (MITI)
10:30 a.m.	Kosan Biosciences Inc. (KOSN)	Cerimon Pharmaceuticals, Inc. (private)
11:00 a.m.	SuperGen Inc. (SUPG)	TorreyPines Therapeutics, Inc. (TPTX)
11:30 a.m.	SciClone Pharmaceuticals, Inc. (SCLN)	Caliper Life Sciences, Inc.
12:30 p.m.	Novavax, Inc. (NVAX)	Pozen, Inc. (POZN)
1:00 p.m.	SGX Pharmaceuticals, Inc. (SGXP)	Light Sciences Oncology, Inc.
1:30 p.m.	VIA Pharmaceuticals Inc. (VIAP)	Barrier Therapeutics Inc. (BTRX)
2:00 p.m.	Lev Pharmaceuticals, Inc. (LEVP)
2:30 p.m.	Dyax Corp. (DYAX)	BioDelivery Sciences International Inc. (BDSI)
3:00 p.m.	XOMA Ltd. (XOMA)	Scynexis, Inc (private)
3:30 p.m.	Ligand Pharmaceuticals Inc. (LGND)	Athersys, Inc. (ATHX)
4:00 p.m.	MorphoSys AG (MPSYY.PK)	Paratek (private)
4:30 p.m.	Anadys Pharmaceuticals Inc. (ANDS)	Idenix Pharmaceuticals Inc. (IDIX)

Wednesday, March 5, 2008
Biotechnology Workshop
Introduction	HCV: The Changing Landscape: Incidence, Prevalence and Diagnostics Stephen R. Lee, Ph.D., CSO, OraSure Technologies, Inc. (OSUR)
Panel I	HCV: Protease Inhibitors and Beyond Achillion Pharmaceuticals, Inc. (ACHN), InterMune, Inc. (ITMN), and Idenix Pharmaceuticals, Inc.(IDIX)
Panel II	HCV: Polymerase Inhibitors Anadys Pharmaceuticals, Inc. (ANDS), Genelabs Technologies, Inc. (GNLB), Idenix Pharmaceuticals, Inc. (IDIX), and Pharmasset, Inc. (VRUS)
Panel III	HCV: Emerging Therapies. How does the Standard of Care Change? Thinking Beyond DAAV GlobeImmune, Inc. (Private), Romark Laboratories, L.C. (Private), and Scynexis, Inc. (Private)
Panel IV	Antibody Technologies: Is There Value in a Platform? Dyax Corp. (DYAX), Medarex, Inc. (MEDX), MorphoSys AG (MOR.GR), and XOMA Ltd. (XOMA)
Lunch
Panel V	Lupus: Crossing the Finish Line, New Therapies for SLE Genelabs Technologies, Inc. (GNLB), Human Genome Sciences Inc. (HGSI), Idera Pharmaceuticals, Inc. (IDRA), and La Jolla Pharmaceutical Company (LJPC) Dr. Jill Buyon, Professor, Division of Rheumatology, New York University; Dr. Joan Merrill, University of Oklahoma, Lupus Foundation of America
Panel VI	MRSA: The Antibiotic Paradox Achillion Pharmaceuticals, Inc. (ACHN), Paratek Pharmaceuticals (Private), and Targanta Therapeutics Corporation (TARG)

Wednesday, March 5, 2008
Time (ET)	Sea/Ocean Room	Arbor Boardroom
8:00 a.m.	Hologic Inc. (HOLX)	Abaxis Inc. (ABAX)
8:30 a.m.	LifeCell Corp. (LIFC)	Sciele Pharma Inc. (SCRX)
9:00 a.m.		Cerus Corp. (CERS)
9:30 a.m.	OraSure Technologies Inc. (OSUR)	Inspire Pharmaceuticals, Inc. (ISPH)
10:00 a.m.		MWI Veterinary Supply, Inc. (MWIV)
10:30 a.m.	Given Imaging Ltd. (GIVN)	Neogen Corp. (NEOG)
11:00 a.m.	Haemonetics Corp. (HAE)	ArQule Inc. (ARQL)
11:30 a.m.	Orthovita Inc. (VITA)	Biosante Pharma Inc (BPAX)
12:30 p.m.	Advanced Life Sciences Holdings, Inc. (ADLS)
1:00 p.m.	Dynavax Technologies Corp. (DVAX)	Obagi Medical Products, Inc. (OMPI)
1:30 p.m.	ViroPharma Inc. (VPHM)	Salix Pharmaceuticals Ltd. (SLXP)
2:00 p.m.	Pharmasset, Inc. (VRUS)	Micrus Endovascular Corp. (MEND)
2:30 p.m.	InterMune Inc. (ITMN)	Anesiva, Inc. (ANSV)
3:00 p.m.	Medarex Inc. (MEDX)	Elite Pharmaceuticals Inc. (ELI)
3:30 p.m.	Millennium Pharmaceuticals Inc. (MLNM)	Albany Molecular Research Inc. (AMRI)